NOVELIX (21)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novelix Pharmaceuticals Limited lists 15,45,000 new equity shares issued at Rs. 20/- on preferential basis pursuant to warrant conversion, … | |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 new equity shares issued at Rs. 20/- on preferential basis pursuant to warrant conversion, with lock-in periods up to June 2027.
| |||||||||||||||
15,45,000 equity shares of Novelix Pharmaceuticals Limited (Scrip Code 536565) issued at Rs. 20/- on preferential basis pursuant to warrant … | |||||||||||||||
15,45,000 equity shares of Novelix Pharmaceuticals Limited (Scrip Code 536565) issued at Rs. 20/- on preferential basis pursuant to warrant conversion, listed and permitted to trade from November 27, 2025.
| |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 equity shares issued at Rs. 20/- on preferential basis pursuant to conversion of warrants, … | |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 equity shares issued at Rs. 20/- on preferential basis pursuant to conversion of warrants, with lock-in periods until June 2026 and 2027.
| |||||||||||||||
BSE announces demat auction for settlement number 747 covering 118 scrips with pending delivery obligations across various quantities. | |||||||||||||||
BSE announces demat auction for settlement number 747 covering 118 scrips with pending delivery obligations across various quantities. | |||||||||||||||
BSE demat auction list for settlement number 747 dated November 3, 2025, containing securities and quantities available for auction. | |||||||||||||||
BSE demat auction list for settlement number 747 dated November 3, 2025, containing securities and quantities available for auction. | |||||||||||||||
BSE announces demat auction settlement 747 covering 118 scrips with specified quantities for settlement dated November 3, 2025. | |||||||||||||||
BSE announces demat auction settlement 747 covering 118 scrips with specified quantities for settlement dated November 3, 2025. | |||||||||||||||
BSE announces changes to Long Term ASM Framework including new securities entering surveillance, stage movements, and securities exiting the … | |||||||||||||||
BSE announces changes to Long Term ASM Framework including new securities entering surveillance, stage movements, and securities exiting the framework effective October 30, 2025.
| |||||||||||||||
BSE announces changes to Long Term ASM Framework effective October 30, 2025, including new securities shortlisted, securities moving to … | |||||||||||||||
BSE announces changes to Long Term ASM Framework effective October 30, 2025, including new securities shortlisted, securities moving to higher/lower stages, and securities moving out of the framework.
| |||||||||||||||
BSE circular detailing the listing of new equity shares of Novelix Pharmaceuticals Limited with lock-in periods ending in March 2026-2027. | |||||||||||||||
BSE circular detailing the listing of new equity shares of Novelix Pharmaceuticals Limited with lock-in periods ending in March 2026-2027.
| |||||||||||||||
BSE circular detailing the listing of new equity shares for Novelix Pharmaceuticals Limited with lock-in periods. | |||||||||||||||
BSE circular detailing the listing of new equity shares for Novelix Pharmaceuticals Limited with lock-in periods.
| |||||||||||||||